Replies to post #249318 on Biotech Values

[dewophile]

re GSK/HBV

Not much benefit to adding interferon to this regimen
SVR 24 for all comers was 9/15% depending on duration of bepi and interferon
for pts w 3k or lower baseline surface ag it was 14/26%
for pts w 1k or lower it was 24/41%
https://www.aasld.org/the-liver-meeting/pegylated-interferon-reduces-relapses-following-bepirovirsen-treatment

As a point of reference Bepi only resulted in 16% SVR in patients with <3k baseline HBSAg on NA therapy

https://www.nejm.org/doi/full/10.1056/NEJMoa2210027

link to AASLD abstract search. Late breakers will be released in a couple weeks. I'll be curious to see the ALGS core inhibitor data :

https://www.aasld.org/search